Natco Gets US FDA Nod for API Unit

  Published 11 months ago

Natco Pharma received a US FDA EIR for its Mekaguda API unit after a June inspection with a single VAI observation.

  • Inspection occurred from June 9–13, 2025; only one observation was noted, categorized as voluntary action indicated (VAI).
  • Regulatory filing confirms receipt of Establishment Inspection Report (EIR), indicating closure of inspection process.
  • Natco develops APIs, generics, specialty drugs, and crop protection products from its Hyderabad-based headquarters.

You might like these

HEG Q1 Profit Jumps 437%, Plans Expansion

P N Gadgil Launches Budget-Friendly Gold Jewelry Brand

India Index Options Turnover Dips Amid Jane Street Embargo

KP Green Engineering Secures Major Orders for Growth

China's Debt Collection: A Looming Crisis

Putin Threatens Tech Giants

Infosys & Telstra Announce Partnership

News that matters the most ⚡